120 g/L and pre-brachytherapy Hb < 120 g/L was 9%, 15% and 22% respectively. The 3 year overall survival rate was 72%, 65% and 49% respectively. 52 patients (38.5%) had anaemia at presentation (Hb < 120 g/L). There was significant association between anaemia and younger age, more advanced stage and lymph node involvement. Anaemia was corrected by blood transfusion and/or ferric carboxymaltose. The pre-brachytherapy Hb level had the strongest impact on both local failure and survival. The post-treatment Hb level did not have an impact on the outcomes.

Conclusion Anaemia in patients with cervical cancer undergoing chemoradiation was a strong prognostic factor for local control and survival. The pre-brachytherapy Hb level had the strongest impact indicating the benefit from correcting the anaemia before treatment and maintaining the Hb level above 120 g/L during the treatment.

Abstracts

2022-RA-1048-ESGO CIRCULATING HPV CELL-FREE DNA IN CERVICAL CANCER

Suzana Mittelstadt, 1Christopher Schroeder, 2Olga Kelemen, 1Tobias Engler, 1Jakob Admard, 1Axel Gschwind, 1André Koch, 1Sarah Elisabeth Wörz, 1Ermst Oberlechner, 2Saasha Hoffmann, 1Jürgen Andreae, 1Felix Nits, 1Bernhard Krämer, 2Inna Bonzheim, 1Anneke Staebler, 1Frank Stubiennauch, 1Thomas Illner, 1Stephan Ossowski, 1Stefan Kommos, 1Department of Women’s Health, Tübingen, Tübingen University Women’s Hospital, Tübingen, Germany; 2Institute for Medical Genetics and Applied Genomics, Tübingen University Women’s Hospital, Tübingen, Germany; 1Institute for Medical Virology and Epidemiology of Viral Disease, Tübingen University Women’s Hospital, Tübingen, Germany

Introduction/Background Human papillomavirus (HPV) related cervical cancer is the fourth most frequent cancer in women worldwide. Currently patient follow-up and therapy monitoring is solely based on clinical examination and cross-sectional imaging. Liquid biopsies for cell-free circulating tumor DNA in cancer are a novel biomarker to detect treatment response, residual disease, and relapse. The aim of this study was to investigate the potential use of cell-free circulating HPV-DNA (cfHPV-DNA) in plasma samples of patients with cervical cancer.

Methodology In this proof-of-concept study cfHPV-DNA levels were measured using a highly sensitive Next-Generation-Sequence-based approach targeting a panel of 13 high-risk HPV-types. For nine patients cfHPV-DNA sequencing was performed.

Results In this proof-of-concept study we were able to detect cfHPV-DNA in plasma samples of patients with primary and recurrent cervical cancer. Our findings may hold potential to develop a powerful and easily accessible tool in cervical cancer management.

Conclusion

2022-RA-1060-ESGO RETROPERITONEAL PARAORTIC LYMPH NODE STAGING IN ADVANCED CERVICAL CANCER: TUNISIAN EXPERIENCE

Souha Jauoudi, Lamia Najia, Leila Achouri, Takoua Chalouati, Azza Chalchoub, Ines Zemmni, Maher Slimane, Monia Hechiche, Tarek Dhib, Riadh Chargui, Khaled Rahal. Oncologic Surgery, Institut Salah Azaiez, Tunis, Tunisia

Introduction/Background Locally advanced cervical cancer is treated with Radio-chemotherapy and brachytherapy. Therefore; a pre-treatment para-aortic lymph node assessment is important for disease staging and therapeutic implications. Our study aimed to analyze the Tunisian experience of laparoscopic lymphadenectomy for patients with locally advanced cervical cancer.

Methodology We reported 29 patients with locally advanced cervical cancer who underwent laparoscopic lymphadenectomy at our Institute between 2016 and 2022.

Results The mean age was 44 years. Patients were staged IIIC1 in 48.2%, 2.1% were IIB, 6.9% were IVA, 6.9% IB1, 6.9% IB3 and 2.8% were IIA2. CT scan and MRI showed suspicious pelvic lymph nodes in 65.5% and suspicious para-aortic lymph nodes in 17.9% of cases. All patients underwent para-aortic lymph node dissection after a mean time of 5 days. Our technique was 68.9% Transperitoneal and 31.01% extraperitoneal. The mean time duration was 2.37 Hours. There was no per-operative or postoperative complications. One patient had a blood transfusion. The mean time of hospital stay was 2 days. Pathological examination found a mean number of 9 Nodes (range 2–22 removed lymph nodes).

Conclusion There was 32.17% of invaded lymph nodes. Sensitivity and specificity were respectively 100% and 83.3%, and VPP was 33.3%. All patients had radiochemotherapy for their cervical cancer.

2022-RA-1067-ESGO IS LAPAROSCOPIC RADICAL HYSTEROECTOMY SAFE IN CERVICAL CANCER WITH TUMOR SIZE ≤2 CM, EVEN IF PARAMETRIAL INVASION OR LYMPH NODE METASTASIS IS FOUND AFTER SURGERY?

Junhwan Kim, 1Seoyeon Lee, 1Se Ik Kim, 1Dong Hoon Suh, 1Yang Beom Kim, 1Jae-Weon Kim, 1Chul Hun Choi, 1Maria Lee. 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea, Republic of; 2Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of; 3Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

Conclusion

10.1136/ijgc-2022-ESGO.86

10.1136/ijgc-2022-ESGO.85

10.1136/ijgc-2022-ESGO.87
**Introduction/Background**
Previously, our research team suggested patients with 2009 FIGO stage IB1 cervical cancer with tumor size ≤2 cm on preoperative magnetic resonance imaging (MRI) were safe candidates as laparoscopic radical hysterectomy (RH) did not influence disease recurrence in this subgroup. We aimed to investigate whether laparoscopic RH is also feasible in parametrial-positive or node-positive, early cervical cancer with a small sized tumor.

**Methodology**
From Cervical Cancer cohorts of three tertiary institutional hospitals, we identified patients with 2009 FIGO stage IB1 who received either open or laparoscopic Type C RH. Among them, those with cervical tumor ≤2 cm on pre-operative MRI and were adherent to the guidelines for adjuvant treatment were included. Patients’ clinicopathologic characteristics and survival outcomes were compared between the laparoscopic and open RH groups. Subgroup analyses were conducted according to the presence or absence of parametrial invasion (PMI) and lymph node metastasis (LN M).

**Results**
In total, 498 patients were included: 299 and 199 for laparoscopic and open RH groups, respectively. After surgery, all study population was managed properly in terms of adjuvant treatment. After a median observation period of 59.4 months, the two groups showed similar progression-free survival (PFS; P=0.615) and overall survival (P=0.439). On pathologic examination, 16 (3.2%) and 49 (9.8%) had PMI and LN M, respectively, and 10 (2.0%) had both. In a subgroup of PMI, no difference in PFS was observed between the laparoscopic and open RH groups (P=0.893). In a subgroup of LN M, the two groups also showed similar PFS (P=0.169). Consistent results were also found in subgroups of non-PMI and non-LNM.

**Conclusion**
Our study results demonstrate that laparoscopic RH might be safe in early cervical cancer with tumor size ≤2 cm, regardless of parametrial and nodal status, when adjuvant treatment is administered properly. Further large cohort studies are warranted to support our findings.

---

**Introduction/Background**
Neuroendocrine carcinoma of the cervix (NECC) is a rare, aggressive histologic type of cervical cancer. Currently, there is no standardized therapy for NECC.

**Methodology**
This study aims to investigate prognostic factors of NECC and compare survival outcomes according to the treatment methods.

**Results**
In total of 47 NECC patients included, mean age at diagnosis was 46.9 years. The most common chief complaint was vaginal bleeding (61.7%). In relation to histologic